vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $23.0M, roughly 1.0× Intellia Therapeutics, Inc.). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -416.2%, a 423.6% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 14.8%). SIFCO INDUSTRIES INC produced more free cash flow last quarter ($8.0M vs $-69.4M). Over the past eight quarters, SIFCO INDUSTRIES INC's revenue compounded faster (8.1% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
NTLA vs SIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $24.0M |
| Net Profit | $-95.8M | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | -428.9% | 10.7% |
| Net Margin | -416.2% | 7.5% |
| Revenue YoY | 78.8% | 14.8% |
| Net Profit YoY | 25.7% | 177.3% |
| EPS (diluted) | $-0.81 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $24.0M | ||
| Q3 25 | $13.8M | $22.8M | ||
| Q2 25 | $14.2M | $22.1M | ||
| Q1 25 | $16.6M | $19.0M | ||
| Q4 24 | $12.9M | $20.9M | ||
| Q3 24 | $9.1M | $21.7M | ||
| Q2 24 | $7.0M | $22.0M | ||
| Q1 24 | $28.9M | $20.5M |
| Q4 25 | $-95.8M | $1.8M | ||
| Q3 25 | $-101.3M | $-429.0K | ||
| Q2 25 | $-101.3M | $3.4M | ||
| Q1 25 | $-114.3M | $-1.4M | ||
| Q4 24 | $-128.9M | $-2.3M | ||
| Q3 24 | $-135.7M | $-443.0K | ||
| Q2 24 | $-147.0M | $72.0K | ||
| Q1 24 | $-107.4M | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | -428.9% | 10.7% | ||
| Q3 25 | -808.9% | -1.7% | ||
| Q2 25 | -772.2% | 14.8% | ||
| Q1 25 | -726.6% | -4.1% | ||
| Q4 24 | -1059.9% | -9.2% | ||
| Q3 24 | -1589.0% | -1.5% | ||
| Q2 24 | -1998.6% | 0.7% | ||
| Q1 24 | -394.0% | -6.5% |
| Q4 25 | -416.2% | 7.5% | ||
| Q3 25 | -735.2% | -1.9% | ||
| Q2 25 | -710.8% | 15.4% | ||
| Q1 25 | -687.6% | -7.3% | ||
| Q4 24 | -1001.2% | -11.1% | ||
| Q3 24 | -1489.5% | -2.0% | ||
| Q2 24 | -2112.6% | 0.3% | ||
| Q1 24 | -371.3% | -7.8% |
| Q4 25 | $-0.81 | $0.29 | ||
| Q3 25 | $-0.92 | $-0.07 | ||
| Q2 25 | $-0.98 | $0.56 | ||
| Q1 25 | $-1.10 | $-0.23 | ||
| Q4 24 | $-1.27 | $-0.38 | ||
| Q3 24 | $-1.34 | $-0.07 | ||
| Q2 24 | $-1.52 | $0.01 | ||
| Q1 24 | $-1.12 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $1.1M |
| Total DebtLower is stronger | — | $39.0K |
| Stockholders' EquityBook value | $671.4M | $38.7M |
| Total Assets | $842.1M | $74.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $1.1M | ||
| Q3 25 | $511.0M | $491.0K | ||
| Q2 25 | $459.7M | $2.0M | ||
| Q1 25 | $503.7M | $1.9M | ||
| Q4 24 | $601.5M | $3.1M | ||
| Q3 24 | $658.1M | $1.7M | ||
| Q2 24 | $691.1M | $3.4M | ||
| Q1 24 | $791.3M | $2.5M |
| Q4 25 | — | $39.0K | ||
| Q3 25 | — | $51.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | $671.4M | $38.7M | ||
| Q3 25 | $748.4M | $36.9M | ||
| Q2 25 | $715.3M | $35.8M | ||
| Q1 25 | $779.9M | $32.4M | ||
| Q4 24 | $872.0M | $33.7M | ||
| Q3 24 | $962.6M | $30.4M | ||
| Q2 24 | $971.1M | $29.8M | ||
| Q1 24 | $1.0B | $29.7M |
| Q4 25 | $842.1M | $74.9M | ||
| Q3 25 | $925.3M | $73.4M | ||
| Q2 25 | $898.9M | $77.3M | ||
| Q1 25 | $986.2M | $78.8M | ||
| Q4 24 | $1.2B | $81.0M | ||
| Q3 24 | $1.2B | $104.6M | ||
| Q2 24 | $1.2B | $106.3M | ||
| Q1 24 | $1.3B | $104.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $8.1M |
| Free Cash FlowOCF − Capex | $-69.4M | $8.0M |
| FCF MarginFCF / Revenue | -301.6% | 33.3% |
| Capex IntensityCapex / Revenue | 0.5% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $8.1M | ||
| Q3 25 | $-76.9M | $726.0K | ||
| Q2 25 | $-99.6M | $371.0K | ||
| Q1 25 | $-148.9M | $2.8M | ||
| Q4 24 | $-85.2M | $-3.8M | ||
| Q3 24 | $-84.8M | $857.0K | ||
| Q2 24 | $-58.2M | $382.0K | ||
| Q1 24 | $-120.7M | $-3.2M |
| Q4 25 | $-69.4M | $8.0M | ||
| Q3 25 | $-76.9M | $566.0K | ||
| Q2 25 | $-99.9M | $310.0K | ||
| Q1 25 | $-149.7M | $2.7M | ||
| Q4 24 | $-86.2M | $-3.9M | ||
| Q3 24 | $-86.1M | $580.0K | ||
| Q2 24 | $-59.2M | $-175.0K | ||
| Q1 24 | $-123.2M | $-3.9M |
| Q4 25 | -301.6% | 33.3% | ||
| Q3 25 | -558.2% | 2.5% | ||
| Q2 25 | -701.0% | 1.4% | ||
| Q1 25 | -900.1% | 14.1% | ||
| Q4 24 | -669.4% | -18.8% | ||
| Q3 24 | -945.2% | 2.7% | ||
| Q2 24 | -850.9% | -0.8% | ||
| Q1 24 | -425.7% | -18.9% |
| Q4 25 | 0.5% | 0.4% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 1.7% | 0.3% | ||
| Q1 25 | 4.4% | 0.8% | ||
| Q4 24 | 7.6% | 0.5% | ||
| Q3 24 | 14.0% | 1.3% | ||
| Q2 24 | 14.5% | 2.5% | ||
| Q1 24 | 8.7% | 3.3% |
| Q4 25 | — | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
